双極性障害市場：カナダの治療薬市場...市場調査レポートについてご紹介

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification
3.3 Symptoms
3.4 Prognosis
4 Disease Management
4.1 Diagnosis Overview
4.1.1 Clinical Evaluation
4.1.2 Screening Tools
4.2 Treatment Overview
4.2.1 Treatment Initiation and Maintenance Therapy
4.2.2 Manic or Mixed Episodes
4.2.3 Acute Agitation
4.2.4 Hypomanic Episodes
4.2.5 Major Depressive Episodes
4.2.6 Rapid Cycling
4.2.7 Cyclothymia
4.2.8 Other Treatment Factors
4.3 Treatment Guidelines and Leading Prescribed Drugs
4.4 Canada
5 Competitive Assessment
5.1 Overview
5.2 Product Profiles – Major Brands
5.2.1 Lithium
5.2.2 Anticonvulsants
5.2.3 Typical Antipsychotics
5.2.4 Atypical Antipsychotics
5.2.5 Antidepressants
5.3 Other Therapeutic Classes
6 Unmet Need and Opportunity
6.1 Overview
6.2 Effective Treatment Options for Bipolar Depression
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Antipsychotics with a Low Risk of EPS and Metabolic Changes
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Mood Stabilizers with Improved Safety Profiles
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 Education for Physicians in Order to Improve Diagnosis Rates
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity
6.6 Novel Drugs Developed Specifically for Bipolar Disorder
6.6.1 Unmet Need
6.6.2 Gap Analysis
6.6.3 Opportunity
7 Pipeline Assessment
7.1 Overview
7.1.1 Clinical Trials by Class of Therapy
7.2 Promising Drugs in Clinical Development
7.2.1 Abilify Maintena
7.2.2 ITI-007
7.3 Off-label Pipeline and Recently Approved Therapies
7.4 Promising Drugs in Early-Stage Development
7.5 Other Drugs in Development
8 Market Outlook
8.1 Canada
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Diagnosed Bipolar Disorder Patients
9.4.2 Percent Drug-Treated Patients
9.4.3 Launch and Patent Expiry Dates
9.4.4 General Pricing Assumptions
9.4.5 Individual Drug Assumptions
9.4.6 Generic Erosion
9.5 Primary Research – KOLs Interviewed for this Report
9.6 Primary Research – Prescriber Survey
9.7 About the Authors
9.7.1 Analyst
9.7.2 Therapy Area Director
9.7.3 Epidemiologist
9.7.4 Global Director of Therapy Research and Analysis
9.8 About GlobalData
9.9 Disclaimer